NEW DELHI: ENTOD Pharmaceuticals has received final approval from the Drug Controller General of India (DCGI) for PresVu eye drops, marking a significant milestone in the management of presbyopia.
This approval follows an earlier recommendation by the Subject Expert Committee of the Central Drugs Standard Control Organisation, a company statement said.
PresVu is the first eye drop in India developed to reduce dependency on reading glasses for individuals affected by presbyopia, a common age-related vision condition that typically impacts those over 40, the company said.
Presvu has also applied for a patent for the invention in terms of its formulation and the process. These eye drops utilise advanced dynamic buffer technology to swiftly adapt to tear pH, ensuring consistent efficacy and safety for extended use.
This approval follows an earlier recommendation by the Subject Expert Committee of the Central Drugs Standard Control Organisation, a company statement said.
PresVu is the first eye drop in India developed to reduce dependency on reading glasses for individuals affected by presbyopia, a common age-related vision condition that typically impacts those over 40, the company said.
Presvu has also applied for a patent for the invention in terms of its formulation and the process. These eye drops utilise advanced dynamic buffer technology to swiftly adapt to tear pH, ensuring consistent efficacy and safety for extended use.